scholarly journals Morbidities and Mortality in Patients with Hereditary Thrombotic Thrombocytopenic Purpura

Author(s):  
Azra Borogovac ◽  
Jessica Anne Reese ◽  
Samiksha Gupta ◽  
James N George

Hereditary thrombotic thrombocytopenic purpura (hTTP) is a rare disorder caused by severe ADAMTS13 deficiency. Major morbidities and death at a young age are common. Although ADAMTS13 replacement can prevent morbidities and death, current regimens of plasma prophylaxis are insufficient. We identified 226 patients with hTTP in 96 reports published from 2001 through 2020. In 202 patients the age at diagnosis was reported; 117 were female, 85 were male. The difference was caused by diagnosis of 34 women during pregnancy, suggesting that many men and nulliparous women are not diagnosed. Eighty-three patients had severe jaundice at birth; hTTP was suspected and effectively treated in only 3 infants. Of the 217 patients who survived infancy, 73 (34%) had major morbidities, defined as stroke, kidney or cardiac injury, that occurred at a median age of 21 years. Sixty-two patients had stroke; 13 strokes occurred in children ≤10 years old. Of the 54 patients who survived their initial major morbidity and were subsequently followed, 37 (69%) had sustained or subsequent major morbidities. Of the 39 patients who were followed past age 40, 20 (51%) had experienced a major morbidity. Compared to age and gender-matched United States population, probability of survival was lower at all ages, beginning at birth. Prophylaxis was initiated in 45 patients with a major morbidity; in 11 (28%) a major morbidity recurred after prophylaxis had begun. Increased recognition of hTTP and more effective prophylaxis begun at a younger age are required to improve health outcomes.

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 447-447
Author(s):  
Maelle Le Besnerais ◽  
Julie Favre ◽  
Cecile V. Denis ◽  
Bernard Lenormand ◽  
Paul Mulder ◽  
...  

Background Thrombotic thrombocytopenic purpura (TTP) is a life-threatening illness caused by deficiency of the Von Willebrand factor (VWF) cleaving protease ADAMTS13. Endothelial injury is believed to be a key initiating event in the pathogenesis leading to platelet activation and formation of platelet-rich thrombi in microvasculature. However, the nature of endothelial injury in TTP is poorly defined and seems to differ among the microvascular territory. Especially, a cardiac injury has recently been identified and hypothesized as a major cause of death in TTP. Methods We used an animal model in which some TTP-like symptoms have been triggered in ADAMTS13 knockout mice (B6.129-ADAMTS13tm1Dgi ) by challenge with 2000 units/kg body weight of recombinant human VWF containing ultra large VWF (rhVWF, Baxter, Vienna Austria). rhVWF was also injected in 6 wild type mice (C57/bl6-B129 WT+VWF) while seven other wild type mice received placebo (WT). Cardiac involvement was assessed by transthoracic echocardiography using validated parameters i.e left ventricular ejection fraction (LVEF), fractional shortening (FS) and cardiac index (CI). Cardiac perfusion was determined by arterial spin labeling MRI (Biospec 47/40 advanced II, Brucker, Ettlingen, Germany). Ex vivo endothelial function analysis in isolated coronary, mesenteric and renal segments were performed using a myograph. Arteries were precontracted by phenylephrine or serotonin and the relaxations induced by increasing concentrations of acetylcholine (receptor-mediated, endothelium-dependent relaxation) or the nitric oxide (NO) donor sodium nitroprusside (SNP; endothelium-independent- relaxation) were assessed. Arteries were also incubated with the NO synthase-inhibitor N-Nitro L-Arginine (LNNA) to assess the contribution of NO to the relaxing responses to acetylcholine (endothelium-dependent NO-independent-relaxation). Results On day 1, VWF-challenged ADAMTS13 KO mice rapidly developed symptoms and severe thrombocytopenia (41.8G/L ± 6.9G/L vs 480.7G/L ± 86.5G/L (WT+VWF) and 1118.6G/L ± 160.8G/L (WT); p<0.001), schistocytosis and a decrease in hematocrit levels (40.9% ± 0.8% vs WT+VWF: 51.3% ± 3,8%; p< 0.05 and WT: 56.1% ± 3%; p< 0.001). On day 2, necropsy revealed that macroscopic lesions were restricted to the heart and consisted of acute myocardial hemorrhage and necrosis. Myocardial necrosis was accompanied by infiltration of lymphocytes and interstitial edema. Minimal, acute tubular necrosis in the kidneys was seen in a few animals. Injection of rhVWF in ADAMTS13 KO mice resulted in a decrease in LVEF (73.8% ± 2.7% vs WT+VWF: 86.6% ± 1.3% and WT: 86.8% ± 1.3%; p< 0.01), in FS (37.3% ± 2.1% vs WT+VWF: 50.1% ± 1.6%; p<0.05 and WT: 50.9% ± 12.8%; p< 0.01) and in CI (1.21 ml/min/g ± 0.09 vs WT+VWF: 1.70 ml/min/g ± 0.14 and WT: 1.66 ml/min/g ± 0.1; p< 0.05) suggesting an early systolic dysfunction. However, cardiac perfusion was not significantly affected on day 2. Administration of rhVWF in ADAMTS13KO mice decreased the NO-mediated relaxing responses to acetylcholine in mesenteric (51.1% ± 14.8% vs WT+VWF: 94.4% ± 1.6%; p< 0.05 and WT: 96.5% ± 2.3%; p< 0.001) and coronary arteries (61.7% ± 12.4% vs WT+VWF: 89.9% ± 6.3% and WT: 96.8% ± 0.9%; p< 0.05) but not in renal arteries. Interestingly, under LNNA, endothelium-dependent relaxations were also markedly affected in coronary arteries (19.3% ± 3.7% vs WT+VWF: 70.2% ± 4.7%; p<0.001) in ADAMTS13KO mice suggesting the role of other endothelium-derived vasoactive factors. In parallel, the relaxing responses to SNP were slightly affected (47.8% ± 13.8% vs WT+VWF: 79.1% ± 13.3% and WT: 80.2% ± 7.2%; p< 0.05), suggesting a strong coronary vascular dysfunction on day 2. Conclusions This experimental study reproduced an animal model in which TTP like symptoms are triggered in ADAMTS13 KO mice by administration of VWF and demonstrated that the heart is the most sensitive target organ with myocardial necrosis and systolic dysfunction. We showed for the first time a strong mesenteric and coronary endothelial dysfunction in an induced-TTP model. It may represent an important trigger of the systemic organs failure occurring in this disease, strengthening the need to define the mechanisms involved in this early vascular injury. Disclosures: Schiviz: Baxter: Employment.


2016 ◽  
Vol 14 (10) ◽  
pp. 1917-1930 ◽  
Author(s):  
M. Le Besnerais ◽  
J. Favre ◽  
C. V. Denis ◽  
P. Mulder ◽  
J. Martinet ◽  
...  

1981 ◽  
Vol 46 (02) ◽  
pp. 571-571 ◽  
Author(s):  
M Pini ◽  
C Manotti ◽  
R Quintavalla ◽  
A G Dettori

1979 ◽  
Author(s):  
H. C. Kwaan

The vascular lesions with microthrombi were studied in 12 patients with thrombotic thrombocytopenic purpura (TTP), diagnosed by the characteristic clinical and laboratory findings and confirmed histologically in each case. While defibrination was not observed, and with only minimal changes in the circulating levels of fibrinogen, fibrin degradation products and plasminogen activator, the microthrombotic lesion was invariably present. Immunofluorescent and histochemical studies indicated that both platelet and fibrin were present in the microthrombi with the platelet components dominant in many cases. Using the fibrin slide method, plasminogen activator was demonstrated in the uninvolved blood vessels but totally absent in the vessels occluded by microthrombi. in contrast, fibrinolysis is always present in the vessels afflicted with other types of thrombosis, such as the microthrombi in disseminated intravascular coagulation. Since circulating fibrinolytic activity was normal in TTP, the absence of vascular fibrinolysis is a local defect due to either inhibition by the platelet deposits or by local vascular damage. The inability of thrombolysis may explain the absence of systemic defibrination and the severity of the disease.


1979 ◽  
Author(s):  
J. G. Kelton ◽  
P. B. Neame ◽  
I. Walker ◽  
A. G. Turpie ◽  
J. McBride ◽  
...  

Thrombotic thrombocytopenic purpura (TTP) is a rare but serious illness of unknown etiology. Treatment by plasmapheresis has been reported to be effective but the mechanism for benefit is unknown. We have investigated the effect of plasmapheresis in 2 patients with TTP by quantitating platelet associated IgG (PAIgG) levels prior to and following plasmapheresis. Both patients had very high levels of PAIgG at presentation (90 and A8 fg IgG/platelet respectively, normal 0-5). in both, the PAIgG levels progressively fell to within the normal range and the platelet count rose following plasmapheresis. One patient remained in remission with normal platelet counts and PAIgG levels. The other relapsed after plasmapheresis and the PAIgG level rose prior to the fall in platelet count. Plasmapheresis was repeated and resulted in normalization of both the platelet count and PAIgG level. It is suggested that plasmapheresis removes antiplatelet antibody or immune complexes which may be of etiological importance in this illness.


2020 ◽  
Author(s):  
Falter Tanja ◽  
Böschen Sibylle ◽  
Manfred Beutel ◽  
Bernhard Lämmle ◽  
Scharrer Inge ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document